Prevalence of factor V Leiden and prothrombin G20210A gene mutation

Basit Öğe Kaydı
dc.contributor.authorIrdem, A
dc.contributor.authorDevecioglu, C
dc.contributor.authorBatun, S
dc.contributor.authorSoker, M
dc.contributor.authorSucakli, IA
dc.date.accessioned2024-04-24T17:37:49Z
dc.date.available2024-04-24T17:37:49Z
dc.date.issued2005
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: To determine the prevalence of factor V Leiden (FVL) and prothrombin gene (PG) 20210A mutations in patients who attended the outpatient clinic and do not have a family history of thrombosis. Methods: We researched FVL and PG20210A mutations in 151 outpatients (92 males and 59 females) who attended the Pediatrics Polyclinic, Medical Faculty, Dicle University, Turkey between May 2002 and July 2002. Peripheral venous bloods (2 cc) with ethylenediaminetetraacetic acid were used to isolate DNA by high pure polymerase chain reaction (PCR). Later, by using light-cycler FVL (Roche) and prothrombin mutation detection kit (Roche) and light-cycler equipment, FVL and PG20210A gene mutations were determined from the samples in the glass capillary tubes by PCR specific adaptation. For active protein C (APC) resistance, STA-STACLOT APC-R Detection Kit was used. Expected values were evaluated with STA equipment and using STA-STACLOT APC-R procedure. Results: The prevalence of heterozygote mutations of FVL was 4.6% and PG20210A was 0.7%. The FVL mutation frequency obtained in our study is lower than the other studies in Turkey, but in correlation with the results of the other Caucasian populations throughout the world. Active protein C resistance in patients carrying heterozygote mutation of FVL has been found in low rates. Factor V Leiden and PG20210A were confronted in high prevalences in patients who suffer venous thrombosis (VT). Conclusion: Scanning of FVL and PG20210A gene mutations may be recommended in high risk groups such as relatives of FVL and PG20210A carriers and relatives of patients with VT, and in during pregnancy, the use of oral contraceptives and before surgery. Routine scanning of FVL and PG20210A gene mutations is not recommended in people who do not have risk factors for VT.en_US
dc.identifier.endpage583en_US
dc.identifier.issn0379-5284
dc.identifier.issue4en_US
dc.identifier.pmid15900364
dc.identifier.scopus2-s2.0-19044364846
dc.identifier.scopusqualityQ2
dc.identifier.startpage580en_US
dc.identifier.urihttps://hdl.handle.net/11468/21199
dc.identifier.volume26en_US
dc.identifier.wosWOS:000229422200013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSaudi Med Jen_US
dc.relation.ispartofSaudi Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titlePrevalence of factor V Leiden and prothrombin G20210A gene mutationen_US
dc.titlePrevalence of factor V Leiden and prothrombin G20210A gene mutation
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu